Extended Data Fig. 1: Subgroup analysis: OS in the (a) overall and (b) HR+ cohorts. | Nature Medicine

Extended Data Fig. 1: Subgroup analysis: OS in the (a) overall and (b) HR+ cohorts.

From: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

Extended Data Fig. 1

CDK, cyclin-dependent kinase; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; OS, overall survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician’s choice of chemotherapy.

Back to article page